Revista medica del Instituto Mexicano del Seguro Social · 2026
[Glycemic control of type 2 diabetes: primary care pre-pandemic versus COVID-19 pandemic].
СтатьяНаблюдательное исследованиеСравнительное исследованиеАннотация на английскомНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Soto-Estrada Guadalupe, Mares-Gutiérrez Yolanda, García-Minjares Manuel, Martínez-González Adrián, Martínez-Franco Adrián Israel
Аннотация
BACKGROUND: Keeping an adequate glycemic control is a major global challenge. Approximately 42% of individuals achieve the recommended HbA1c targets.
OBJECTIVE: To compare glycemic control in 2 independent cohorts of patients with type 2 diabetes mellitus treated before and during the COVID-19 pandemic in primary care in Mexico City.
MATERIAL AND METHODS: Analytical observational study; records of 3598 patients with 2 HbA1c determinations (2562 pre-pandemic and 1036 pandemic) from 213 health units were analyzed. Means, proportions, and t and chi-squared tests were calculated; metabolic control was defined as HbA1c ≤ 8%.
RESULTS: Mean HbA1c was 9.1% in both groups in the first measurement; at the last measurement, it was lower in the pre-pandemic group (8.0% vs. 8.3%; p < 0.001). The percentage of controlled patients increased from 38.5% to 58.5% pre-pandemic and from 37.8% to 54.2% during the pandemic (p = 0.017). Dual oral therapy achieved the greatest increase in control (22.5% pre-pandemic, 28.3% pandemic); isolated insulin therapy and absence of pharmacological treatment were less effective under pandemic conditions.
CONCLUSIONS: The pandemic was associated with lower glycemic control; however, regimens with 1 or 2 oral antidiabetic agents retained their effectiveness. Ensuring continuity of care, drug supply, and support for lifestyle measures will be crucial in future crises.
OBJECTIVE: To compare glycemic control in 2 independent cohorts of patients with type 2 diabetes mellitus treated before and during the COVID-19 pandemic in primary care in Mexico City.
MATERIAL AND METHODS: Analytical observational study; records of 3598 patients with 2 HbA1c determinations (2562 pre-pandemic and 1036 pandemic) from 213 health units were analyzed. Means, proportions, and t and chi-squared tests were calculated; metabolic control was defined as HbA1c ≤ 8%.
RESULTS: Mean HbA1c was 9.1% in both groups in the first measurement; at the last measurement, it was lower in the pre-pandemic group (8.0% vs. 8.3%; p < 0.001). The percentage of controlled patients increased from 38.5% to 58.5% pre-pandemic and from 37.8% to 54.2% during the pandemic (p = 0.017). Dual oral therapy achieved the greatest increase in control (22.5% pre-pandemic, 28.3% pandemic); isolated insulin therapy and absence of pharmacological treatment were less effective under pandemic conditions.
CONCLUSIONS: The pandemic was associated with lower glycemic control; however, regimens with 1 or 2 oral antidiabetic agents retained their effectiveness. Ensuring continuity of care, drug supply, and support for lifestyle measures will be crucial in future crises.